JP5752593B2 - 口腔感染の治療および予防組成物 - Google Patents
口腔感染の治療および予防組成物 Download PDFInfo
- Publication number
- JP5752593B2 JP5752593B2 JP2011505396A JP2011505396A JP5752593B2 JP 5752593 B2 JP5752593 B2 JP 5752593B2 JP 2011505396 A JP2011505396 A JP 2011505396A JP 2011505396 A JP2011505396 A JP 2011505396A JP 5752593 B2 JP5752593 B2 JP 5752593B2
- Authority
- JP
- Japan
- Prior art keywords
- composition
- present
- catechin
- sanguinarine
- benzofuran
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title claims description 25
- 230000002265 prevention Effects 0.000 title description 4
- 206010048685 Oral infection Diseases 0.000 title description 2
- INVGWHRKADIJHF-UHFFFAOYSA-N Sanguinarin Chemical compound C1=C2OCOC2=CC2=C3[N+](C)=CC4=C(OCO5)C5=CC=C4C3=CC=C21 INVGWHRKADIJHF-UHFFFAOYSA-N 0.000 claims description 25
- -1 catechin polyphenols Chemical class 0.000 claims description 25
- 229930015421 benzophenanthridine alkaloid Natural products 0.000 claims description 15
- 235000013824 polyphenols Nutrition 0.000 claims description 14
- IANQTJSKSUMEQM-UHFFFAOYSA-N benzofuran Natural products C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 claims description 13
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 claims description 12
- 235000005487 catechin Nutrition 0.000 claims description 12
- 229950001002 cianidanol Drugs 0.000 claims description 12
- 239000000284 extract Substances 0.000 claims description 12
- LLEJIEBFSOEYIV-UHFFFAOYSA-N chelerythrine Chemical compound C1=C2OCOC2=CC2=CC=C3C4=CC=C(OC)C(OC)=C4C=[N+](C)C3=C21 LLEJIEBFSOEYIV-UHFFFAOYSA-N 0.000 claims description 11
- FCEXWTOTHXCQCQ-UHFFFAOYSA-N Ethoxydihydrosanguinarine Natural products C12=CC=C3OCOC3=C2C(OCC)N(C)C(C2=C3)=C1C=CC2=CC1=C3OCO1 FCEXWTOTHXCQCQ-UHFFFAOYSA-N 0.000 claims description 8
- 230000001580 bacterial effect Effects 0.000 claims description 8
- 230000015572 biosynthetic process Effects 0.000 claims description 8
- 229940084560 sanguinarine Drugs 0.000 claims description 8
- YZRQUTZNTDAYPJ-UHFFFAOYSA-N sanguinarine pseudobase Natural products C1=C2OCOC2=CC2=C3N(C)C(O)C4=C(OCO5)C5=CC=C4C3=CC=C21 YZRQUTZNTDAYPJ-UHFFFAOYSA-N 0.000 claims description 8
- RATMHCJTVBHJSU-UHFFFAOYSA-N Dihydrochelerythrine Natural products C1=C2OCOC2=CC2=C(N(C)C(O)C=3C4=CC=C(C=3OC)OC)C4=CC=C21 RATMHCJTVBHJSU-UHFFFAOYSA-N 0.000 claims description 7
- 210000000214 mouth Anatomy 0.000 claims description 7
- 240000006365 Vitis vinifera Species 0.000 claims description 6
- 235000014787 Vitis vinifera Nutrition 0.000 claims description 6
- 150000008622 benzophenanthridines Chemical class 0.000 claims description 6
- 150000001907 coumarones Chemical class 0.000 claims description 6
- 244000269722 Thea sinensis Species 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 241000245971 Eupomatia laurina Species 0.000 claims description 4
- 244000299461 Theobroma cacao Species 0.000 claims description 4
- 241000009298 Trigla lyra Species 0.000 claims description 4
- 235000002532 grape seed extract Nutrition 0.000 claims description 4
- 235000010181 horse chestnut Nutrition 0.000 claims description 4
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims description 3
- 206010006326 Breath odour Diseases 0.000 claims description 3
- 235000006468 Thea sinensis Nutrition 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 235000015218 chewing gum Nutrition 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 239000002324 mouth wash Substances 0.000 claims description 3
- XMOCLSLCDHWDHP-SWLSCSKDSA-N (+)-Epigallocatechin Natural products C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-SWLSCSKDSA-N 0.000 claims description 2
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 claims description 2
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 claims description 2
- 241000157282 Aesculus Species 0.000 claims description 2
- 241000157280 Aesculus hippocastanum Species 0.000 claims description 2
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 claims description 2
- 244000001385 Sanguinaria canadensis Species 0.000 claims description 2
- 235000009470 Theobroma cacao Nutrition 0.000 claims description 2
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 claims description 2
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 claims description 2
- 241000219094 Vitaceae Species 0.000 claims description 2
- 125000003277 amino group Chemical group 0.000 claims description 2
- 235000001046 cacaotero Nutrition 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 229940112822 chewing gum Drugs 0.000 claims description 2
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 claims description 2
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 claims description 2
- 235000012734 epicatechin Nutrition 0.000 claims description 2
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 claims description 2
- 235000021021 grapes Nutrition 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 230000007505 plaque formation Effects 0.000 claims description 2
- 238000002844 melting Methods 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 8
- 230000000844 anti-bacterial effect Effects 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 230000000843 anti-fungal effect Effects 0.000 description 5
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 5
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000002538 fungal effect Effects 0.000 description 4
- WEEFNMFMNMASJY-UHFFFAOYSA-M 1,2-dimethoxy-12-methyl-[1,3]benzodioxolo[5,6-c]phenanthridin-12-ium;chloride Chemical compound [Cl-].C1=C2OCOC2=CC2=CC=C3C4=CC=C(OC)C(OC)=C4C=[N+](C)C3=C21 WEEFNMFMNMASJY-UHFFFAOYSA-M 0.000 description 3
- SDWZWUUOXFFJSA-UHFFFAOYSA-N 4-(5-prop-1-enyl-1-benzofuran-2-yl)benzene-1,3-diol Chemical compound C=1C2=CC(C=CC)=CC=C2OC=1C1=CC=C(O)C=C1O SDWZWUUOXFFJSA-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 102000004366 Glucosidases Human genes 0.000 description 3
- 108010056771 Glucosidases Proteins 0.000 description 3
- 241000557116 Macleaya <angiosperm> Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229940121375 antifungal agent Drugs 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 229930182783 neolignan Natural products 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- FGMNOLGACVXOQL-UHFFFAOYSA-N 1-(2,4-dimethoxyphenyl)-2-phenoxyethanone Chemical compound COC1=CC(OC)=CC=C1C(=O)COC1=CC=CC=C1 FGMNOLGACVXOQL-UHFFFAOYSA-N 0.000 description 2
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 2
- 108010021511 Aspergillus oryzae carboxyl proteinase Proteins 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- 206010018785 Gingival infections Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000000619 acesulfame-K Substances 0.000 description 2
- 102000004139 alpha-Amylases Human genes 0.000 description 2
- 108090000637 alpha-Amylases Proteins 0.000 description 2
- 229940024171 alpha-amylase Drugs 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000019439 ethyl acetate Nutrition 0.000 description 2
- 229940074391 gallic acid Drugs 0.000 description 2
- 235000004515 gallic acid Nutrition 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 0 *c(cc1)cc2c1[o]c(-c(c(O)c1)ccc1O)c2 Chemical compound *c(cc1)cc2c1[o]c(-c(c(O)c1)ccc1O)c2 0.000 description 1
- SDWZWUUOXFFJSA-NSCUHMNNSA-N 2-(2,4-dihydroxyphenyl)-5-(E)-propenylbenzofuran Chemical compound C=1C2=CC(/C=C/C)=CC=C2OC=1C1=CC=C(O)C=C1O SDWZWUUOXFFJSA-NSCUHMNNSA-N 0.000 description 1
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 1
- PKVBZABQCCQHLD-UHFFFAOYSA-N 2-bromo-1-(2,4-dimethoxyphenyl)ethanone Chemical compound COC1=CC=C(C(=O)CBr)C(OC)=C1 PKVBZABQCCQHLD-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010063045 Effusion Diseases 0.000 description 1
- 229930182598 Eupomatenoid Natural products 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 208000032139 Halitosis Diseases 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000331121 Krameria lappacea Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- CWEZAWNPTYBADX-UHFFFAOYSA-N Procyanidin Natural products OC1C(OC2C(O)C(Oc3c2c(O)cc(O)c3C4C(O)C(Oc5cc(O)cc(O)c45)c6ccc(O)c(O)c6)c7ccc(O)c(O)c7)c8c(O)cc(O)cc8OC1c9ccc(O)c(O)c9 CWEZAWNPTYBADX-UHFFFAOYSA-N 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 210000004513 dentition Anatomy 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000008368 mint flavor Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 229940041672 oral gel Drugs 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 229920000137 polyphosphoric acid Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 229920002414 procyanidin Polymers 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- KNFUWJAIDVAYOV-ONEGZZNKSA-N rataniaphenol II Chemical compound CC=1C2=CC(/C=C/C)=CC=C2OC=1C1=CC=C(O)C=C1 KNFUWJAIDVAYOV-ONEGZZNKSA-N 0.000 description 1
- KNFUWJAIDVAYOV-UHFFFAOYSA-N rataniaphenol II Natural products CC=1C2=CC(C=CC)=CC=C2OC=1C1=CC=C(O)C=C1 KNFUWJAIDVAYOV-UHFFFAOYSA-N 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000036346 tooth eruption Effects 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Description
本発明は、口腔感染の治療および予防に有用である、ベンゾフェナントリジンアルカロイド、ベンゾフラン化合物およびカテキンポリフェノールを含む組成物に関する。
口内における細菌または真菌の膜の形成は、非常に多くの場合、う歯、歯槽膿漏ならびに歯根膜および歯肉の感染のような障害を生じる。特に、細菌または真菌膜の形成は、インプラント歯科学、義歯の維持および一般に高齢の歯科患者において非常に一般的である。
本発明は、
口腔内における細菌および真菌膜の形成を低減し、したがって口臭および歯垢の形成を低減する抗細菌、抗真菌および抗酵素活性を有する、
a)ベンゾフェナントリジンアルカロイド;
b)ベンゾフラン化合物;および
c)カテキンポリフェノール
を含む組成物に関する。
a)サンギナリンおよび/またはケレリトリンおよび/またはこれらの誘導体から選択されるベンゾフェナントリジンアルカロイド;
b)上記に特定されたベンゾフラン化合物;
c)モノマーまたはオリゴマーカテキンポリフェノール
を含む組成物に関する。
a)ベンゾフェナントリジンアルカロイド:0.5〜10mg;
b)ベンゾフラン:5〜25mg;
c)ポリフェノール化合物:10〜100mg。
a)ベンゾフェナントリジンアルカロイド:2.5〜5mg;
b)ベンゾフラン化合物:3〜10mg;
c)ポリフェノール化合物:40〜50mg。
工程A. 2−フェノキシ−2',4'−ジメトキシアセトフェノン(a)の調製
25mLの2−ブタノン中の2−ブロモ−2',4'−ジメトキシアセトフェノン(5g、19.1mmol)の溶液を、20.0mLの同じ溶媒中のフェノール(1.8g、19.1mmol)、K2CO3(2.6g、19.1mmol)およびKI(41.5mg、0.25mmol)の懸濁液に加えた。次に溶液を20時間還流した。混合物を濾過し、溶媒を真空下で蒸発させた。得られた残渣をEtOAcに溶解し、NaOHの10%水溶液、次に水で洗浄した。有機抽出物をNa2SO4で乾燥し、濾過し、真空下で蒸発させた。最後に、粗残渣をEt2Oで洗浄し、低圧で乾燥して、4.4g(収率:84%)の標記化合物をもたらした。
12gのポリリン酸を、130.0mLのキシレン中の工程Aで得られた化合物(4.4g、16.2mmol)の溶液に加えた。混合物を2時間環流し、次に室温に放置して冷ました。次に、溶液をデカントし、低圧で蒸発させた。得られた残渣(3.7g、収率:90%)を、更に精製することなく次の工程に使用した。
工程Bで調製した化合物(3.7g、14.5mmol)およびピリジン塩酸塩(11.1g、96.4mmol)の混合物を、225℃で45分間加熱した。形成された赤色生成物を10%HClに注いだ。混合物をEtOAcで繰り返し洗浄し、合わせた有機層をNa2SO4で乾燥し、蒸発させた。提供するために、残渣をカラムクロマトグラフィー(ヘキサン/EtOAc=7:3)により精製して、最終化合物を、ベンゼンからの結晶化の後、収率41%(1.36g)で得た。
ベンゾフェナントリジンアルカロイド 2.5mg
ベンゾフラン化合物 10.0mg
ブドウ(Vitis vinifera)抽出物 50.0mg
キシリトール 500.0mg
マンニトール 400.0mg
カンゾウ風味剤 50.0mg
ステアリン酸マグネシウム 10.0mg
アセスルファムK 5.0mg。
ベンゾフェナントリジンアルカロイド 3.0mg
ベンゾフラン化合物 10.0mg
茶(Camellia sinensis)抽出物 50.0mg
グリセリン 400.0mg
液体ソルビトール 200.0mg
ヒドロキシエチルセルロース 30.0mg
ミント風味剤 20.0mg
メチルパラヒドロキシベンゾエート 10.0mg
アセスルファムK 5.0mg
精製水 2.0gにする十分量。
Claims (10)
- a)サンギナリンおよび/またはケレリトリンであるベンゾフェナントリジンアルカロイド;
b)前記ベンゾフラン化合物;
c)モノマーまたはオリゴマーカテキンポリフェノール
を含む、請求項1に記載の組成物。 - 種々の成分が、以下のインターバル(1単位用量あたりの重量):
a)サンギナリンまたはケレリトリン:0.5〜10mg;
b)ベンゾフラン化合物:5〜25mg;
c)カテキンポリフェノール:10〜100mg
で存在する、請求項1または2に記載の組成物。 - 種々の成分が、以下のインターバル(1単位用量あたりの重量):
a)サンギナリンまたはケレリトリン:2.5〜5mg;
b)ベンゾフラン化合物:3〜10mg;
c)カテキンポリフェノール:40〜50mg
で存在する、請求項3に記載の組成物。 - ベンゾフェナントリジンアルカロイドのサンギナリンまたはケレリトリンが、遊離もしくは塩化形態、実質的に純粋なそのままの形態、またはサングイナリアカナデンシス、マクレアヤコルダタもしくはマクレアヤマクロカルパの抽出物の形態で存在する、請求項1〜4のいずれかに記載の組成物。
- 前記ベンゾフェナントリジンアルカロイドが、ルテイン酸で塩化された形態で存在する、請求項5に記載の組成物。
- ベンゾフラン化合物が、クラメリアトリアンドラ、エウポマティアラウリナまたはピペル属種の抽出物の形態で存在する、請求項1〜6のいずれかに記載の組成物。
- カテキンポリフェノールが、カテキン、エピカテキンおよびガロカテキン、ならびにC3ヒドロキシルでのその没食子酸エステルのいずれかの単位の形態で存在する、請求項1〜7のいずれかに記載の組成物。
- カテキンポリフェノールが、ブドウ(Vitis vinifera)、セイヨウトチノキ(Aesculus hippocastanum)、茶(Camellia sinensis)またはカカオ(Theobroma cacao)の種または地上に生えている部分の抽出物の形態で存在する、請求項8に記載の組成物。
- 口溶け錠剤、口内洗浄剤、口腔内に分散するゲル剤、またはチューインガムの形態である、請求項1〜9のいずれかに記載の組成物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITMI20080746 ITMI20080746A1 (it) | 2008-04-24 | 2008-04-24 | Composizioni per il trattamento e la prevenzione delle infezioni del cavo orale |
ITMI2008A000746 | 2008-04-24 | ||
EP08425422.6 | 2008-06-12 | ||
EP08425422A EP2133076B1 (en) | 2008-06-12 | 2008-06-12 | Compositions for the treatment and prevention of infections of the oral cavity |
PCT/EP2009/002515 WO2009129926A1 (en) | 2008-04-24 | 2009-04-06 | Compositions for the treatment and prevention of infections of the oral cavity |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2011518792A JP2011518792A (ja) | 2011-06-30 |
JP5752593B2 true JP5752593B2 (ja) | 2015-07-22 |
Family
ID=41061271
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011505396A Expired - Fee Related JP5752593B2 (ja) | 2008-04-24 | 2009-04-06 | 口腔感染の治療および予防組成物 |
Country Status (10)
Country | Link |
---|---|
US (1) | US8496975B2 (ja) |
EP (1) | EP2268276A1 (ja) |
JP (1) | JP5752593B2 (ja) |
KR (1) | KR20100134685A (ja) |
CN (1) | CN102014892A (ja) |
AU (1) | AU2009240294B2 (ja) |
CA (1) | CA2722209C (ja) |
IL (1) | IL208848A (ja) |
RU (1) | RU2504378C2 (ja) |
WO (1) | WO2009129926A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1402018B1 (it) * | 2010-10-11 | 2013-08-28 | Indena Spa | Formulazioni per il trattamento delle affezioni delle prime vie respiratorie. |
CN104145967B (zh) * | 2014-07-29 | 2016-02-03 | 中国人民解放军第二军医大学 | 血根碱在制备抗真菌生物被膜药物中的应用 |
KR20180006522A (ko) | 2016-07-07 | 2018-01-18 | 삼성디스플레이 주식회사 | 액정 조성물 및 이를 포함하는 액정 표시 장치 |
US11865107B2 (en) * | 2018-11-21 | 2024-01-09 | Asclepius Pharmaceutical, LLC | Pharmaceutical composition |
JP7129957B2 (ja) * | 2019-08-19 | 2022-09-02 | 信越化学工業株式会社 | 口腔内崩壊錠用組成物及びその製造方法並びにこれを用いた口腔内崩壊錠及びその製造方法 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62126128A (ja) * | 1985-11-27 | 1987-06-08 | Sato Seiyaku Kk | 抗菌剤 |
US4908211A (en) * | 1986-09-08 | 1990-03-13 | Paz Armando F | Chewing gum and ingredients to chemically inhibit formation of plaque and calculus |
JPH07106972B2 (ja) * | 1987-04-24 | 1995-11-15 | 佐藤製薬株式会社 | 歯科口腔用薬剤 |
IL86802A0 (en) * | 1987-06-30 | 1988-11-30 | Vipont Pharma | Drug delivery devices |
NZ232572A (en) * | 1989-03-13 | 1991-11-26 | Vipont Pharma | Oral rinse composition containing a benzophenanthridine alkaloid extract from sanguinaria canadesis |
US5066483A (en) * | 1989-03-13 | 1991-11-19 | Vipont Pharmaceutical, Inc. | Oral rinse compositions |
JP2588031B2 (ja) * | 1989-08-21 | 1997-03-05 | 太陽化学株式会社 | 茶ポリフェノール化合物含有口腔洗浄剤 |
DK0464297T3 (da) * | 1990-07-05 | 1995-10-09 | Indena Spa | Komplekser af neolignanderivater med phospholipider, anvendelsen deraf samt farmaceutiske og kosmetiske formuleringer indeholdende disse |
JP3154712B2 (ja) * | 1990-07-26 | 2001-04-09 | インデナ・ソチエタ・ペル・アチオニ | ネオリグナン誘導体と燐脂質との複合体、その使用法及び該複合体を含む製薬学的及び化粧品的製剤 |
IT1284971B1 (it) * | 1996-10-17 | 1998-05-28 | Indena Spa | Formulazioni farmaceutiche e cosmetiche ad attivita' antiacne |
IT1284970B1 (it) * | 1996-10-17 | 1998-05-28 | Indena Spa | Formulazioni farmaceutiche e cosmetiche ad attivita' antimicrobica |
JP4845359B2 (ja) * | 2004-09-16 | 2011-12-28 | 弘 竹田 | 口腔ケア用組成物 |
US8895084B2 (en) * | 2004-12-23 | 2014-11-25 | Colgate-Palmolive Company | Oral care composition containing extract of unoxidized Camellia |
JP5963383B2 (ja) * | 2005-06-06 | 2016-08-03 | 株式会社明治 | 口腔ケア用組成物 |
EP1882473A1 (en) * | 2006-07-28 | 2008-01-30 | Indena S.P.A. | Use of anthocyanosides to prepare formulations for the treatment of mucositis induced by antitumoral drugs |
-
2009
- 2009-04-06 JP JP2011505396A patent/JP5752593B2/ja not_active Expired - Fee Related
- 2009-04-06 AU AU2009240294A patent/AU2009240294B2/en not_active Ceased
- 2009-04-06 RU RU2010143220/15A patent/RU2504378C2/ru active
- 2009-04-06 EP EP09735454A patent/EP2268276A1/en not_active Withdrawn
- 2009-04-06 CN CN2009801140232A patent/CN102014892A/zh active Pending
- 2009-04-06 KR KR1020107023536A patent/KR20100134685A/ko not_active Application Discontinuation
- 2009-04-06 CA CA2722209A patent/CA2722209C/en active Active
- 2009-04-06 WO PCT/EP2009/002515 patent/WO2009129926A1/en active Application Filing
- 2009-04-06 US US12/988,870 patent/US8496975B2/en active Active
-
2010
- 2010-10-21 IL IL208848A patent/IL208848A/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
CN102014892A (zh) | 2011-04-13 |
CA2722209A1 (en) | 2009-10-29 |
US8496975B2 (en) | 2013-07-30 |
IL208848A (en) | 2013-06-27 |
AU2009240294B2 (en) | 2014-04-10 |
JP2011518792A (ja) | 2011-06-30 |
KR20100134685A (ko) | 2010-12-23 |
EP2268276A1 (en) | 2011-01-05 |
US20110091392A1 (en) | 2011-04-21 |
RU2504378C2 (ru) | 2014-01-20 |
WO2009129926A8 (en) | 2009-12-30 |
WO2009129926A1 (en) | 2009-10-29 |
AU2009240294A1 (en) | 2009-10-29 |
IL208848A0 (en) | 2011-01-31 |
RU2010143220A (ru) | 2012-05-27 |
CA2722209C (en) | 2017-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2591673C (en) | Compositions comprising extracts from sanguinaria or macleaya | |
KR101870979B1 (ko) | 상기도 장애 치료용 제제 | |
TWI421097B (zh) | 用作抗微生物劑之增強劑的查耳酮 | |
JP5752593B2 (ja) | 口腔感染の治療および予防組成物 | |
US20140314686A1 (en) | Polyphenol/flavonoid compositions and methods of formulating oral hygienic products | |
CA2895249C (en) | Topical oral composition for alleviating dry mouth symptoms and for treating mouth ulcers | |
US20080286213A1 (en) | Pharmaceuticals for treating or preventing oral diseases | |
EP2133076B1 (en) | Compositions for the treatment and prevention of infections of the oral cavity | |
US20080287527A1 (en) | Pharmaceuticals for treating or preventing oral diseases | |
KR20170065944A (ko) | 비수용성 항염 성분 및 아미노산계 계면활성제를 포함하는 구강 조성물 | |
US20080287525A1 (en) | Pharmaceuticals for treating or preventing oral diseases | |
ITMI20080746A1 (it) | Composizioni per il trattamento e la prevenzione delle infezioni del cavo orale | |
US20080287526A1 (en) | Pharmaceuticals for treating or preventing oral diseases | |
EP2470175B1 (en) | Fulvic acid compositions and their use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120328 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130827 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20131127 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20131204 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131226 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20140410 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140826 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141106 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150421 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150520 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5752593 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |